Author:
Wu Zhuozhuo,Shan Qungang,Jiang Yuyue,Wang Ziyin,Zhuang Yaping,Liu Jingjing,Li Tiankuan,Yang Ziyu,Wei Tao,Wen Chenlei,Cui Wenguo,Qiu Zilong,Huang Wei,Liu Xiaoyu,Wang Zhong-min
Reference54 articles.
1. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade;G Morad;Cell,2022
2. Neoadjuvant immune checkpoint blockade: A window of opportunity to advance cancer immunotherapy;S L Topalian;Cancer Cell,2023
3. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions;M Yi;Mol Cancer,2022
4. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer;H Zhang;J Exp Clin Cancer Res,2021
5. Challenges and Opportunities for Pancreatic Cancer Immunotherapy;A S Bear;Cancer Cell. Dec